STAT1 and hepatocellular carcinoma: Thus, 125I treatment can inhibit the proliferation of HCC cells, with this effect being attenuated by the downregulation of STAT1. It is confirmed by the CCK-8 assay that STAT1-RNAi blocked the anti-proliferation effect of 125I treatment (Figure 4E).